Establishing a blood-based biomarker panel for pre-clinical Alzheimer’s disease

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1136602

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The current gold standard biomarkers for Alzheimer’s disease (AD) are uneconomical and invasive, thus impeding early treatment prior to irreversible damage. I posit that biochemical changes associated with the disease are reflected in the blood several years prior to the clinical manifestation of the disease. Therefore, I propose to investigate these changes in individuals predisposed to AD, prior to the appearance of clinical symptoms, to identify biomarkers for the early diagnosis of AD.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2021

Funding Scheme: Targeted Calls

Funding Amount: $716,778.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Neurosciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Alzheimer disease | amyloid beta-protein | biomarkers | blood | neuroscience

Related Links